Diplomat Pharmacy (DPLO) PT Raised to $40 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Leerink Partners Maintains OP Following Diplomat Pharmacy (DPLO) Q1
May 12, 2015 11:14 AM EDTLeerink Partners maintains an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $40.00 (from $36.00), following the release on the 1Q15 results. Diplomat reported an adjusted EPS of $0.09 (+57% y/y), which was $0.01 ahead of Leerink estimates and consensus. Total revenue of $625M increased +34% y/y. Revenue was slightly ahead of Leerink estimate
but below consensus.
Leerink analyst, David Larsen, commented on the... More
Diplomat Pharmacy (DPLO) Tops Q1 EPS by 1c; Boosts FY15 Outlook
May 11, 2015 4:08 PM EDTDiplomat Pharmacy (NYSE: DPLO) reported Q1 EPS of $0.09, $0.01 better than the analyst estimate of $0.08. Revenue for the quarter came in at $625 million versus the consensus estimate of $629.6 million.
Diplomat Pharmacy sees FY2015 EPS of $0.48-$0.51, versus prior guidance of $0.47-$0.50 and the consensus of... More
